Recent 8-K filings for IDXG

• May 14, 2026, 4:15 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Interpace Biosciences Q1 2026 revenue $9.0M, thyroid revenue up 12% YoY; reaffirms 16% growth guidance

  Q1 revenue $9.0M; GAAP down 22% YoY due to PancraGEN exit, but Pro Forma revenue up 14% to $9.0M from $7.9M.

• April 1, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Interpace Q4 revenue $9.2M, thyroid revenue +14% YoY; debt fully paid off

  Q4 revenue $9.2M, FY revenue $38.7M; Q4 income from cont. ops $22.8M (includes one-time tax adjustment).

• January 20, 2026, 6:59 PM ET other material materiality 0.85 positive item 2.02item 7.01item 9.01

  Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Guidance, and Preferred Stock Conversion

  Preliminary 2025 thyroid testing revenue of ~$34-35M, up 21% over prior year.

• December 3, 2025, 6:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Interpace Biosciences fully repays BroadOak term loan early, strengthens balance sheet

  Fully repaid outstanding term loan facility with BroadOak Capital Partners prior to maturity.

• November 12, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Interpace Biosciences Reports Q3 2025 Revenue of $8.8M, Thyroid Test Volume Up 12% YoY

  Q3 2025 revenue $8.8M, up 22% pro forma vs prior year; operating income $1.1M

• August 8, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Interpace Biosciences Q2 revenue down 23% to $9.2M; loss from continuing ops $0.5M

  Net revenue $9.2M (-23% YoY); loss from continuing ops $0.5M vs income $2.5M a year ago.

• May 8, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Interpace Q1 revenue $11.5M (+13% YoY); guides FY2025 ~$38M

  Net revenue $11.5M (+13% YoY); income from continuing ops $1.8M vs $0.8M.

• May 1, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 2.05item 8.01item 9.01

  Interpace Biosciences restructures after Medicare LCD ends PancraGEN coverage

  Medicare LCD L39365 ends PancraGEN reimbursement as of April 24, 2025; no specimens after May 2.

• March 6, 2025, 6:59 PM ET other material materiality 0.85 negative item 4.02

  Interpace Biosciences to restate 2023 and quarterly 2023/2024 financials due to accrued royalty errors

  Accrued royalties overstated by $5.3M to $7.1M across 2023 and 2024 quarterly balance sheets.

• January 27, 2025, 6:59 PM ET regulatory materiality 0.90 positive item 2.05item 8.01item 9.01

  Interpace Biosciences: CMS delays Genetic Testing LCD to April 24, 2025; Company re-evaluates restructuring plan

  CMS directed Medicare contractors to delay implementation of LCD L39365 from Feb 23 to April 24, 2025.

• January 21, 2025, 6:59 PM ET other material materiality 0.85 negative item 1.01item 2.03item 2.05

  Interpace restructures debt and cuts workforce after CMS drops PancraGEN coverage

  Fourth Amendment: monthly $500k principal payments Feb-Jun 2025, interest-only Jul-Dec, final balance due Dec 31, 2025; 1% restructuring fee paid on Jan 17, 2025.

• January 10, 2025, 6:59 PM ET regulatory materiality 0.75 negative item 8.01item 9.01

  CMS final LCD denies coverage for Interpace's PancraGEN test; company to discontinue after Feb 7, 2025

  CMS issued final LCD L39365 establishing non-coverage for PancraGEN, a DNA-based test assessing pancreatic cyst cancer risk.

• November 13, 2024, 6:59 PM ET other materiality 0.10 neutral item 5.07

  Stockholders ratify appointment of EisnerAmper as auditor for FY2024

  Over 10.97M shares voted FOR ratification, 13,711 against, 2,680 abstained.

• November 6, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Interpace Biosciences Q3 revenue $12.3M, record test volume, swings to profit

  Q3 net revenue $12.3M, up 35% YoY ($9.1M); test volume up 26% to record levels.

• October 15, 2024, 7:59 PM ET other material materiality 0.65 positive item 1.01item 3.02item 3.03item 5.03item 7.01item 9.01

  Interpace exchanges all Series B Preferred for Series C Preferred; first step toward Nasdaq uplisting

  All 47,000 Series B Preferred shares (28,000 Ampersand, 19,000 1315 Capital) exchanged for Series C at $1,000 stated value.

• August 2, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Interpace Q2 revenue $12.0M (+9% YoY); operating income $2.2M vs $0.8M

  Test volume up 12% YoY to record levels; sixteenth consecutive quarter of YoY volume growth.

• May 9, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Interpace Q1 revenue $10.3M (+4% YoY); income from ops $0.6M; record test volume +10%

  Q1 net revenue $10.3M, up 4% YoY from $9.8M; test volume up 10% to record levels.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event earnings

11 positive 5 negative 1 neutral

source · IDXG on sec.gov